Announcements Trials

Browse Landscape

Phase

Status

Completed 2 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Zollinger-Ellison Syndrome 1

Interventions

Cyclophosphamide 166 Docetaxel 154 Bevacizumab 153 Carboplatin 148 Gemcitabine 146 Cisplatin 146 pembrolizumab 142 Radiotherapy 135 Paclitaxel 132 Capecitabine 122 Rituximab 115 Oxaliplatin 104 Fluorouracil 103 Nivolumab 94 Irinotecan 85 Doxorubicin 85 Pemetrexed 83 Leucovorin 82 Dexamethasone 82 fludarabine 74 fludarabine phosphate 72 Bortezomib 69 Etoposide 67 Erlotinib Hydrochloride 66 Cetuximab 65 Methotrexate 58 Trastuzumab 56 Cytarabine 54 Lenalidomide 50 Everolimus 49

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Terminated × YF 476 × Clear all

NCT02454075 2021-01-29

YF476 and Type II Gastric Carcinoids

Trio Medicines Ltd.

Phase 2 Terminated

3 enrolled 11 charts

Zollinger-Ellison Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡